261
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study

, , , , , , , , , , & show all
Pages 647-653 | Received 07 Dec 2017, Accepted 01 May 2018, Published online: 21 May 2018

References

  • Anselmi, M., et al., 2006. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis, 185, 114–120.
  • Aoki, T., et al., 2015. Relationship between carotid artery intima-media thickness and small dense low-density lipoprotein cholesterol concentrations measured by homogenous assay in Japanese subjects. Clinica chimica acta, 442, 110–114.
  • Arsenault, B.J., et al., 2007. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. European heart journal, 28, 2770–2777.
  • Berneis, K.K., and Krauss, R.M., 2002. Metabolic origins and clinical significance of LDL heterogeneity. Journal of lipid research, 43, 1363–1379.
  • Boekholdt, S.M., et al., 2012. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. The journal of the American medical association, 307, 132–139.
  • Di Angelantonio, E., et al., 2009. Major lipids, apolipoproteins, and risk of vascular disease. The journal of the American medical association, 302, 1993–2000.
  • Di Angelantonio, E., et al., 2012. Lipid-related markers and cardiovascular disease prediction. The journal of the American medical association, 30, 2499–2506.
  • Ding, D., et al., 2014. Serum lipids, apolipoproteins, and mortality among coronary artery disease patients. BioMed research international, 5, 1–11.
  • Dyslipidemia Panel of the International Atherosclerosis Society Panel members. 2014. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia-full report. Journal of clinical lipidology, 8, 29–60.
  • Ehara, S., et al., 2001. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 103, 1955–1960.
  • Hirayama, S., and Miida, T., 2012. Small dense LDL: an emerging risk factor for cardiovascular disease. Clinica chimica acta, 414, 215–224.
  • Holvoet, P., et al., 2001. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology, 21, 844–848.
  • Hoogeveen, R.C., et al., 2014. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arteriosclerosis, thrombosis, and vascular biology, 34, 1069–1077.
  • Jacobson, T.A., et al., 2015. National lipid association recommendations for patients-centered management of dyslipidemia: part 1-full report. Journal of clinical lipidology, 9, 129–169.
  • Johnston, N., et al., 2006. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. International journal of cardiology, 113, 167–173.
  • Koba, S., et al., 2008. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. Journal of atherosclerosis and thrombosis, 15, 250–260.
  • Lamon-Fava, S., Diffenderfer, M.R., and Marcovina, S.M., 2014. Lipoprotein(a) metabolism. Current opinion in lipidology, 25, 189–193.
  • Masson, W., et al., 2015. Association between LDL-C, Non HDL-C, and Apolipoprotein B levels with coronary plaque regression. Arquivos brasileiros de cardiologia, 105, 11–19.
  • Meisinger, C., et al., 2005. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation, 112, 651–657.
  • Ray, K.K., et al., 2014. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidemias 2011. European heart journal, 35, 960–968.
  • Reiner, Z., et al., 2011. ESC/EAS Guidelines for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European heart journal, 32, 1769–1818.
  • Smith Jr, S.C., et al., 2006. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerostic vascular disease: 2006 update: endorsed by the National Heart Lung, and Blood Institute. Circulation, 113, 2363–2372.
  • Sniderman, A.D., et al., 2010. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? Journal of clinical lipidology, 4, 152–155.
  • Steinberg, D., et al., 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. The New England journal of medicine, 320, 915–924.
  • Steinberg, D. and Lewis, A., 1997. Conner memorial lecture: oxidative modification of LDL and atherosclerosis. Circulation, 95, 1062–1071.
  • Toshima, S., et al., 2000. Circulating oxidized-low-density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arteriosclerosis, thrombosis, and vascular biology, 20, 2243–2247.
  • Varbo, A., et al., 2013. Remnant cholesterol as a causal risk factor for ischemic heart disease. Journal of the American college of cardiology, 61, 427–436.
  • Voros, S., et al., 2013. Apoprotein B, small-dense LDL and impaired HDL remodeling is associated with larger plaque burden and more noncalcified plaque as assessed by coronary CT angiography and intravascular ultrasound with radiofrequency backscatter: results from the ATLANTA I Study. Journal of the American heart association, 2, e000344.
  • Wallenfeldt, K., et al., 2004. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. Journal of internal medicine, 56, 413–420.
  • Wenbrenner, T., et al., 2003. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis, 168, 99–106.
  • Xu, R.X., et al., 2014. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids in health and disease, 13, 188.
  • Zhang, Y., et al., 2015. Lipoprotein subfractions partly mediate the association between serum uric acid and coronary artery disease. Clinica chimica acta, 441, 109–114.
  • Zhang, Y., et al., 2016. Non-HDL-C is a better predictor for the severity of coronary atherosclerosis compared with LDL-C. Heart lung and circulation, 25, 975–981.
  • Zhu, C.G., et al., 2015. Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. Journal of clinical lipidology, 9, 794–800.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.